Taisho Pharmaceutical Co., Ltd.

Kaigene Licenses Next-Generation FcRn Inhibitor KG006 to Taisho for Japan in Deal Worth Up to $351 Million

- Kaigene grants Taisho Pharmaceutical exclusive rights to develop and commercialize FcRn inhibitor KG006 in Japan, receiving a $5 million upfront payment. - The deal includes up to $22 million plus ¥57.5 billion JPY (~$351 million) in milestone payments, plus tiered royalties on Japanese net sales. - The agreement establishes a three-way MRCT collaboration among Kaigene, Taisho, and Celltrion to accelerate global Phase 3 development of KG006. - KG006 is a next-generation subcutaneous FcRn inhibitor targeting autoantibody-mediated autoimmune diseases with potential best-in-class properties.